Investigator-driven randomised controlled trial of cefiderocol vs standard therapy for healthcare associated and hospital acquired Gram-negative bloodstream infection (GAMECHANGER)

Paterson, D. L. and Sulaiman, H. and Po-Yu, L. and Chatfield, M. and Yilmaz, M. and Salmuna, Z. N. and Mazlan, M. Z. and Anunnatsiri, S. and Sirijatuphat, R. and Chotiprasitsakul, D. and Lye, D. and Somani, J. and Kalimuddin, S. and Thamlikitkul, V. and Lee, Y. T. and Lin, Y. T. and Yang, Y. S. and Wan Ramli, Wan Nurliyana and Ong, H. C. and Mootsikapun, P. and Meesing, A. and Tseng, C. H. and Yeh, T. K. and Hashim, A. M. B. and Puangpatra, P. and Aslan, A. T. and Santanirand, P. and Chiang, T. T. and Archuleta, S. and Chan, Y. F. Z. and Chia, P. Y. and Sahin, M. and Yigitbasi, A. A. and Forde, B. and Wright, H. and Stewart, A. and Ling, W. P. and Rossi, V. and Harris-Brown, T. and Harris, P. N. A. (2024) Investigator-driven randomised controlled trial of cefiderocol vs standard therapy for healthcare associated and hospital acquired Gram-negative bloodstream infection (GAMECHANGER). CMI Communications, 1 (Suppl. 1). p. 4751. E-ISSN 2950-5909

PDF (Abstract) - Published Version Restricted to Repository staff only Download (634kB) | Request a copy

Abstract

Background : Cefiderocol has in vitro activity against multi-drug resistant (MDR) and extensively-drug resistant (XDR) gram-negative bacilli. It is FDA- and EMA-approved, but efficacy in bloodstream infections (BSI) is uncertain. We undertook a multicentre, open label, randomised trial comparing cefiderocol with standard of care (SOC) antibiotics in patients with hospital-acquired or healthcare-associated BSI caused by gram-negative bacilli (NCT03869437). Methods: We enrolled adult patients from 17 sites in 6 countries. Participants were randomised <48 hours post initial blood culture collection 1:1 to cefiderocol (2 grams over 3 hours, frequency determined by renal function) or SOC, as determined by the treating team. The primary outcome was all-cause mortality at day 14. Secondary outcomes included 30 and 90-day mortality, clinical and microbiology failure at day 14, microbiological failure up to day 90, colonisation or infection with MD organisms or Clostridioides difficile infection. Our hypothesis was that cefiderocol was non-interior to SOC using a margin of 10% for the primary outcome. Results: 513 patients were enrolled, from 9,144 screened (Figure 1). The main analysis population comprised 504 patients (cefiderocol=250, SOC=254;Figure 1). BSI sources were diverse (UTI 19%, intravascular line-related 18%, intra-abdominal 17%, pneumonia 12%). 59% patients were immunosuppressed, including 21% with haematologic malignancies. 11% BSIs were polymicrobial. The most commonly isolated organisms from index blood cultures were E. coli (in 33% patients), Klebsiella pneumonia (in 30% patients), Pseudomonas spp. (11% patients) and Acinetobacter spp. (8% patients). 121/504 (24%) were infected with >1 carbapenem-resistant isolate, as determined by site microbiology laboratories. 20/250 (8.0%) patients randomized to cefiderocol met the primary outcome of mortality at 14 days. compared with 17/254 (6.7% )randomized to SOC (risk difference 1.3%, 95% CI: 3.2% to 5.9%; RR 1.20 95% CI: 0.64 to 2.23), demonstrating non-inferiority (Table 1, Figure 2). Conclusions: Cefiderocol for hospital-acquired or healthcare-associated gram-negative BSI was non-inferior, but not superior, to SOC.

Item Type:	Article (Abstract)
Additional Information:	7208/120697
Subjects:	R Medicine > RC Internal medicine > RC111 Infectious and Parasitic Diseases
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button):	Kulliyyah of Medicine > Department of Internal Medicine Kulliyyah of Medicine
Depositing User:	Dr Wan Nurliyana Wan Ramli
Date Deposited:	25 Apr 2025 12:21
Last Modified:	25 Apr 2025 16:23
URI:	http://irep.iium.edu.my/id/eprint/120697

Actions (login required)

View Item